Pro-apoptotic protein–protein interactions of the extended N-AChE terminus by Toiber, Debra et al.
BASIC NEUROSCIENCES, GENETICS AND IMMUNOLOGY - ORIGINAL ARTICLE
Pro-apoptotic protein–protein interactions of the extended
N-AChE terminus
Debra Toiber Æ David S. Greenberg Æ Hermona Soreq
Received: 3 February 2009/Accepted: 28 May 2009/Published online: 16 June 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract The N-terminally extended ‘‘synaptic’’ acetyl-
cholinesterase variant N-AChE-S operates to promote
apoptosis; however, the protein partners involved in this
function remain unknown. Here, we report that when
microinjected to fertilized mouse oocytes, N-AChE-S
caused embryonic death as early as the zygotic stage. To
identify the putative protein partners involved, we ﬁrst tried
yeast two hybrid screening, but this approach failed,
probably because of the N-AChE-S-induced lethality. In
contrast, sequence analysis and a corresponding peptide
array revealed possible partners, which were validated by
co-immunoprecipitation. These include the kinases GSK3,
Aurora and GAK, the membrane integrin receptors, and the
death receptor FAS. Each of these could potentially mod-
ulate N-AChE-S-induced apoptosis with possible thera-
peutic value for the treatment of Alzheimer’s disease.
Keywords Acetylcholinesterase  
Apoptosis, N-AChE-S   Neurodegeneration  
Protein–protein interactions
Introduction
Molecular evidence points to two principal apoptotic
pathways leading to neuron death in Alzheimer’s disease
(AD). The amyloid cascade hypothesis attributes the
neurodegenerative process observed in AD brains to a
complex series of events triggered by abnormal pro-
cessing of APP, the amyloid precursor protein of Ab.
This causes deposition of aggregates and neurotoxicity of
the Ab derivative of APP, disrupting calcium homeo-
stasis. Production of free radicals and inﬂammation
ensue leads to neuronal damage (Parihar and Hemnani
2003). However, neuron loss in AD is selective and
occurs particularly in the cholinergic basal nuclei, hip-
pocampus and neocortex (Coyle et al. 1983), and the
amyloid hypothesis does not provide an explanation for
the cholinergic loss in AD. Combination of the amyloi-
dogenic and cholinergic pathways may thus provide an
in-depth view of the processes leading to the initiation
and progression of AD.
The cholinergic hypothesis states that the cognitive
impairments in AD stem from the loss of cholinergic
function (Terry and Buccafusco 2003).This hypothesis is
supported by postmortem anatomical ﬁndings in AD
patients, verifying substantial loss of cholinergic neurons.
Dysfunction of the cholinergic system is indeed, by itself,
sufﬁcient to produce memory deﬁcits in animal models,
which are analogous symptoms to those observed in Alz-
heimer’s dementia (Gordon et al. 1995; Herholz et al.
2000, 2004; Ikarashi et al. 2004; Rees et al. 2003; Rees and
Brimijoin 2003). Accordingly, AChE inhibitors serve to
ameliorate symptoms by prolonging ACh availability
(Mesulam 2004). Some argue for attenuation of the disease
process under treatment with AChE inhibitors (Nordberg
et al. 2006; Recanatini and Valenti 2004), others develop
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kinase, glycogen synthase kinase 3 (GSK3) (Bhat et al.
2004; Huang and Klein 2006), or other key proteins of the
apoptotic pathway, but it is still unclear if these different
approaches reﬂect a single targeted cascade and if so, what
triggers this cascade.
Intriguingly, the known principal AD-associated
mutations all converge in impaired Ca
2? homeostasis
which is also predicted to activate the AChE promoter.
Speciﬁcally, this involves changes in calcium signaling
through the CCAAT motif located -1,270 to -1, 248
from the start codon. This motif binds to the CCAAT
binding factor (CBF/NF-Y) (Wan et al. 2006; Zhu et al.
2007c). Also, NFATc3 and NFATc4 which are activated
by calcineurin during apoptotic signaling are responsible
for AChE expression (Zhu et al. 2007a, b, c). Recipro-
cally, under thapsigargin-induced calcium imbalance and
apoptosis, N-AChE-S is upregulated, whereas its silenc-
ing by siRNA prevented thapsigargin-induced cell death.
Moreover, over-expression of the N-terminally extended
N-AChE-S variant induces apoptosis both in primary
cortical cells and in different cell lines of various tissue
and species origins, attributing to this protein a conserved
and ubiquitous role as a general trigger of apoptosis
(Toiber et al. 2008). N-AChE-S causes cell death and
morphological impairments in primary brain cultures by
activating an apoptotic pathway that includes activation
of GSK3, Bax and caspases. Moreover, N-AChE-S
overexpression was upregulated in AD brains and
showed positive correlation with hyperphosphorylated
Tau (Toiber et al. 2008). However, the mechanism
through which N-AChE-S initiates the apoptotic pathway
remains uncertain.
The core domain of N-AChE-S is positioned extracel-
lularly, whereas its extended N terminus protrudes into the
cytoplasm (Toiber et al. 2008). Therefore, we hypothesized
that N-AChE-S lethality stems from protein partners
interacting with the extended N terminus. To challenge this
hypothesis, we used two hybrid screening and peptide array
screens, with co-immunoprecipitation for validation.
Materials and methods
Circular dichroism measurements
N-AChE peptide was dissolved in double-distilled water to
a ﬁnal concentration of 1 9 10
-4 M. Direct CD spectra
were recorded at room temperature using a CD J-810
spectropolarimeter (Jasco, Easton, MD) with a 100-QS
1-mm path-length quartz cuvette (Hellma, Mu ¨llheim,
Germany). Recordings were at 0.5-nm intervals in the
spectral range 185–260 nm.
Two-hybrid screen
The two-hybrid screen was carried out by Hybrigenics
(Paris, France). A plasmid containing 66 amino acids of the
unique N-AChE N-terminal was sent and cloned into their
proprietary two-hybrid vectors.
Peptide array
The synthetic N-terminal peptide of mouse N-AChE was
diluted in PBS to the ﬁnal concentration of 500 lg/ml, and
added to 96 wells in NUNC-IMMUNO PLATE (F96
MAXSORP Cat 442404) to a ﬁnal volume of 100 ll, for
overnight incubation. Supernatant (sup) was discarded and
the plate washed three times in PBT [5 min, room tem-
perature (RT)]. Protein extracts (100 lg) were added in a
ﬁnal volume of 100 ll for 2 h at RT. Following washes as
above, blocking buffer (5% skim milk in PBT) was added
(1 h at RT). Sup was discarded and primary antibody was
added, diluted 1:100 in the blocking buffer (2 h, RT).
Following an additional round of wash, secondary antibody
diluted 1:10,000 in blocking buffer was added (2 h, RT).
Detection followed repeated wash, with 100 ll 3,30,5,50-
tetramethylbenzidine (TMB, light protected). When bind-
ing occurred, the TMB turned blue, reaction was stopped
by addition of 50 ll1MH 2SO4. Absorbance at 450 nm
served to evaluate the binding efﬁciency.
Results
Lethality of N-AChE-S in microinjected
mouse embryos
Transgenic animals are commonly used as models to
study the effect of enforced over-expression of genes
in the live organism. To substantiate the lethality of
N-AChE-S, we microinjected fertilized mouse oocytes;
this generated relatively small litters (2–3 mice per
female), with none of the newborn carrying the transgene
[compared to a minimum 8% of transgenic animals when
microinjected with control, non-lethal genes (Steward
et al. 1982)]. In search of the developmental stage(s)
where embryonic death took place, we analyzed the
microinjected embryos before implantation. Most of the
N-AChE-S injected embryos did not develop further than
the two-cell stage and only one of them developed to a
blastocyst; however, it presented massive morphological
impairments (Fig. 1 and data not shown). For comparison,
water-injected embryos all survived to reach morula and
blastocyst stages. Together, this indicated that N-AChE-S
over-expression is already lethal at the zygotic stage.
Because the shorter AChE-S is not lethal and yields viable
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suspected that the extended N terminus was the cause.
Sequence considerations of the N-AChE terminus
The human exon hE1e encodes the N-AChE extended N
terminus, 66 amino acids. Using SwissProt, this protein
sequence was screened for homology against all known
proteins, as well as for structure predictions and protein
modiﬁcation sites. No signiﬁcant homology was found for
this new protein sequence in the database. Intriguingly, the
hE1e translation product includes 15 positively charged
residues (11 arginines, 1 lysines, 3 histidines), making it an
extremely positively charged peptide, with a pI of 11.76.
Such high pI values are often found for histones and other
nucleic acid binding proteins (http://www.expasy.org/tools/
tagident.html).
The extended N-terminal domain translated from hE1e
is in frame with the signal peptide (MRPPQCLLHTPSLAS
PLLLLLLWLLGGGVGA, position 1-31) of the regular
AChE protein. This signal peptide is normally cleaved off
during protein maturation (Fournier et al. 1992). The
addition of the extended N terminus masks the signal
peptide, potentially preventing its cleavage. This would
result in a protein larger by 96 (66 ? 30) amino acid res-
idues, compared to the regular AChE. The very hydro-
phobic signal peptide would then become an alternative
trans-membrane region, similar to the neurexin and
cyclooxygenase proteins (Dean et al. 2003). The resultant
N-AChE protein would then possess a 66 residues long
protrusion at the other side of the plasma membrane
from the enzyme’s core domain, similar to neuroligins
(Ichtchenko et al. 1996).
Sequence analysis revealed that the N-extended termi-
nus of AChE carries multiple consensus sites for predicted
protein–protein interactions and/or modiﬁcations that
potentially participate in signal transduction. These include
an SH3 interaction domain as well as binding sites
Fig. 1 N-AChE-S induced cell death in early embryonic stage.
Mouse embryos were microinjected with an N-AChE-S expression
vector or DDW for control. Results are presented as percent of cells in
each cellular stage. N-AChE-S N = 43, and Ctrl N = 30
Fig. 2 Predicted protein motifs of the N extended AChE. The
N-extended AChE tail forecasts interaction with cell signaling
proteins involved in different cellular pathways (eukaryotic linear
motif) http://elm.eu.org. Peptide sequence: MSCPDRTLVTKVRSHP
SGNQHRPTRGGSRSFHCRRGVRPRPAALRVLPRCPAFSDAA
Fig. 3 Circular dichroism evidence for natural unfolding of the
murine extended N terminus. a Prediction of the disorder domain of
the N-AChE terminus. b Shown is the proﬁle of the 46 amino acids of
the N-extended terminus of mouse AChE. Note the characteristic
shape of an unfolded protein. Y axis: delta E (Delta e = eL - eR),
showing the difference in extinction coefﬁcients for left- and right-
handed circularly polarized light. X axis: wavelength (yellows,
predicted unfolded structure, red N-peptide)
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motifs served for planning experiments to ﬁnd new possi-
ble partners.
The N-extended protein is naturally unfolded
The N-extended terminus was predicted to be a naturally
unfolded peptide, as was demonstrated by circular
dichroism (CD). The secondary structure of a synthetic
peptide carrying this sequence was determined by CD
spectroscopy in the ‘‘far-uv’’ spectral region (190–250 nm).
At these wavelengths the chromophore is the peptide bond,
and the signal arises when it is located in a regular, folded
environment. CD signals reﬂect an average of the entire
molecular population and may report the existence of
alpha-helix, beta-sheet and random coil structures, each





Category Function Processes Component Reference
HCN1 3 B Sodium channel, voltage gated Apical protein, ion transport Cell membrane,
axons, dendrites
GeneID: 348980
ASH1L 1 D DNA binding, RNA polyII
transcription factor activity,
metal binding
Chromatin modiﬁcation Nucleus, Golgi GeneID: 55870
EIF4A2 1 D Translation Initiation factor,
ATP binding
Translation Cytosolic GeneID: 1974












COPS5 15 E Peptidase activity,
Transcription co-activator,
metal binding
Cell cycle, translation Cytoplasm,
Signalosome
GeneID: 10987
RNF123 5 E Ligase activity, metal binding Ubiquitin catabolic process Cytoplasm GeneID: 63891














ST13 7 E Protein binding, bridging Protein folding Cytoplasm GeneID: 6767
UBQLN1 5 E Kinase binding Protein modiﬁcation process Cytoplasm, Nucleus GeneID: 29979
B. Gene or clone ID # of clones Category Gene or clone ID # of clones Category
GID: 13445029 1 C GID: 21955084 1 D
GID: 22024561 1 D GID: 2337879 1 D
GID: 15668106 1 D GID: 22038612 1 D
GID: 21955084 1 D GID: 19774385 2 D
GID: 21427685 1 D GID: 46395361 3 D
GID: 21622701 1 D GID: 2815548 4 D
GID: 7768673 7 D GID: 22024561 1 D
GID: 6670859 1 D GID: 13445029 1 C
GID: 23462906 1 D GID: 13445029 1 C
GID: 21955084 1 D GID: 22024561 1 D
GID: 9857986 1 D GID: 15668106 1 D
GID: 21954909 1 D GID: 21955084 1 D
GID: 21427685 1 D
(A) Known transcripts, (B) unknown transcripts, for further details, see Entrez Genome NCBI database http://www.ncbi.nlm.
nih.gov/sites/entrez?db=gene. The category column notes the reliability of the results, as follows: A very high, B high, C good, D moderate
conﬁdence in the interaction identiﬁed through one unique prey fragment (singleton), E these interactions involve at least one domain of
interaction that might be a potential false positive
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trum. The tested peptide emerged as a naturally unfolded
protein (Fig. 3), which implies ‘‘promiscuous’’ protein–
protein interaction features because of its ﬂexibility.
N-AChE protein–protein interactions
To discover the protein partners interacting with the N
terminus, we ﬁrst attempted a yeast two hybrid screening;
however, yeast cells expressing N-AChE terminus were
unable to survive. Next, we used an optimized two-hybrid
screening which again yielded very few possible protein
partners with weak binding properties, possibly due to the
lethality of this protein (Table 1). That none of those
found partners showed tight interactions, called for
alternative search technologies. The peptide array we
employed next differs substantially from two-hybrid
screening, which uses a chimeric protein, in a nuclear
environment. Nuclear interactions with the chimeric
domains (in both, the bait and the prey) may yield false
positives, whereas, cytoplasmic interactions may be
overlooked. In the case of toxic peptides, very few protein
interactions would be observed in this in vivo system. The
peptide array overcomes these limitations, because the
synthetic environment is indifferent to toxic effects. False
positive interactions were excluded by the use of negative
controls, leading to some plausible partners for the
N-AChE terminus.
ELISA-based reactions primarily tested N-AChE inter-
actions with those target proteins predicted by the sequence
analysis. A synthetic peptide comprising the mouse
N-AChE terminal 46 amino acid residues was tested for its
possible interactions with three candidate proteins: inte-
grin, involved in signal transduction from the cell mem-
brane, for example in AD (ffrench-Constant and Colognato
2004; Ho et al. 2005); Aurora kinase members, involved in
Fig. 5 Co-immunoprecipitation 293 cells were transfected with GFP
or N-AChE-S and the protein extract used for Co-Ip a Negative
control was without antibody. In each experiment four samples were
used GFP input, N-AChE-S (NS) Input and GFP co-IP, NS Co-IP.
b Westerns were probed with anti-AChE which yields a speciﬁc band
at 75 kD. The IP was considered speciﬁc if the band appeared in the
NS IP and not GFP IP. The lower stronger band is nonspeciﬁc.
Antibodies that yielded positive interactions: GSK3, JAB1(CSN5),
Fas, GAK and integrin
Fig. 4 Peptide array for protein interactions: a Positive control. Note
the ﬁrst two bars detection compared to the negative controls. b Dose
dependence. Different concentrations of the synthetic peptide were
added to the plate, and detected by the N-speciﬁc antibody, showing
the sensitivity of the assay. c Positive interaction
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123cell cycle regulation (Kollareddy et al. 2008; Taylor and
Peters 2008), and ﬁnally Apaf, a proapoptotic protein, part
of the apoptosome complex (Fig 4) (Bao and Shi 2007).
Integrin, Aurora kinase and APAF showed interaction,
whereas three different proteins did not interact (not
shown). Integrin which showed a promising interaction and
other proteins known to be involved in the apoptotic
signaling cascade, i.e., GSK3, GAK (cyclin G associated
kinase), JAB1/CSN5, integrin and Fas (TNF receptor
super-family, member 6) were further subjected to
co-immunoprecipitation. Positive co-precipitation (Fig. 5)
served as a validating test, supporting the notion of
co-interaction with these tested partner proteins.
N-AChE-S protein multimers with integrin receptors
were also observed. Integrin receptors are known to inter-
act with many other cellular receptors and be involved in
cell signaling, including the observed GSK3 activation
and dephosphorylation of GSK3 by activation of Protein
Phosphatase 2A (Ivaska et al. 2002). In addition, N-AChE-S
showed a speciﬁc interaction with GSK3, fortifying the
importance of this enzyme in the N-AChE-S apoptotic
pathway (Toiber et al. 2008).
Discussion
Unusual AChE forms were reported in AD (Navaratnam
et al. 1991) and in dementia (Shen 1997). In addition, some
of the commercially available anti-AChE antibodies
yield double bands around 66–70 kDa [see, for example
(Belbeoc’h et al. 2003; Brenner et al. 2003; Meshorer et al.
2004; Morel et al. 2001)]. Sucrose gradient analyses also
reveal yet unexplained diversity of the various AChE iso-
forms (Massoulie 2002). These observations could poten-
tially reﬂect the new, longer member(s) of the AChE
family; and the potent labeling of brain AChE-like protein
with anti-N antibodies (Meshorer et al. 2004) suggests
abundance of such variants.
The novel human N-AChE protein variant shows simi-
larity to the murine protein, supporting the notion that it is
physiologically relevant. In addition to the N-terminal
extension, the new protein spans the very hydrophobic
sequence of the former signal peptide, which becomes a
trans-membrane domain in N-terminally extended AChE
variants. Parallel examples include the asialoglycoprotein
receptor (Spiess and Lodish 1986), the bovine adrenal
dopamine b-monooxygenase (Taljanidisz et al. 1989),
a-neurexin (an extended form of b-neurexin) (Ushkaryov
et al. 1994), and cyclooxygenase (Chandrasekharan et al.
2002). For the extended N-AChE variants, positioning of
the ‘‘conservative’’ signal peptide in the membrane would
enable direct docking of AChE to the cell membrane,
independently of the structural PRiMA, or ColQ proteins
necessary to adhere AChE-S tetramers to the synapse
(Massoulie 2002) (Krejci et al. 1997).
Together with the N-terminal extension, the AChE
protein is enlarged by 20%. However, its catalytic activity
is unaffected, suggesting that the extended N terminus
forms a structurally independent domain, distinct from the
globular AChE structure (Sussman et al. 1991) and sepa-
rated from it by the conservative signal peptide. This fur-
ther implies that the role of the N terminus is not related to
AChE’s catalytic characteristics.
ThepotentialpartnersfortheextendedAChENterminus,
as deduced from the sequence analysis, tested in the peptide
array or by co-immunoprecipitation experiments included
Cyclin G associated kinase (GAK) which contributes to cell
signaling andinternalizationof clathrin-coated vesicles,and
which is probably involved in the mechanism by which
N-AChE-S is internalized. Also included was JAB1/CSN5,
which is involved in the regulation of p53, and could have a
role in preventing N-AChE-S-induced cell death (Lee et al.
2006).GSK was previouslyshown by us(Toiber etal. 2008)
to be involved with N-AChE apoptosis.
Parallel heterodimers formation with other cell mem-
brane receptors such as p75, TRK or FAS family members,
can likewise, activate additional signaling mechanisms.
FAS, which also interacts with N-AChE-S is a known
death receptor, which interacts with caspases and with
death ligands, inducing cell death from a variety of stimuli.
The interaction of N-AChE-S with Fas could induce
mutual activation, leading to known apoptotic cascades.
Together, this data suggests possible protein partners ini-
tiating the N-AChE-S-induced apoptotic cascade and/or
protection from it. Blockade of the apoptogenic partners to
prevent the neuronal associated N-AChE-S cell death in
AD should be considered.
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